Evaluation of the Effect of Pharmacokinetics of Metformin on Survival and Prognosis of Endometrial Cancer

Background: Endometrial cancer can be considering as prevalent cancer in women. Metformin can be considered as anti-tumorigenic agent for several malignancy especially cancer of endometrium. Materials and methods: We collected data of 400 patients who referred to tumor clinic of Motahari clinic from year 2007 until 2017. Patients divided in three groups:1) diabetic cases under treatment by metformin,2) diabetic cases under treatment by other anti-diabetic medications or insulin, 3) non-diabetic cases. Data analyzed by SPSS software and compared using ANOVA and Chi-square test. Results: From 400 patients,115 cases, who have type 2 diabetes and 285 cases without diabetes.68 patients from 115 diabetic participants were under treatment with metformin and 47 patients under treatment with other anti-diabetic medications. 89% of patients in metformin group, 74% of patients in other anti-diabetic drugs group and 74% of non-diabetic cases have two-year survival.83% of in metformin group,65% of in other anti-diabetic drugs group and 66% of non-diabetic cases have five-year survival. The least mortality were reported in metformin users and the most mortality of were reported in non-diabetic patients. Conclusions: Metformin can be considered as an appropriate anti-diabetic pharmacologic drug in patient with endometrial cancer because can decrease risk of mortality and decrease recurrence of endometrial cancer and can improve 2 and 5 year survival rate. We recommend utilization of metformin in women with endometrial cancer.

Keywords:

Endometrial cancer , Diabetes , Metformin